List of Filspari drug patents

Filspari is owned by Travere.

Filspari contains Sparsentan.

Filspari has a total of 1 drug patent out of which 0 drug patents have expired.

Filspari was authorised for market use on 17 February, 2023.

Filspari is available in tablet;oral dosage forms.

Filspari can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.

Drug patent challenges can be filed against Filspari from 2027-02-17.

The generics of Filspari are possible to be released after 29 March, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(6 years from now)

Do you want to check out FILSPARI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 17, 2030
New Chemical Entity Exclusivity (NCE) Feb 17, 2028

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 2027-02-17

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in